Melis V, Zabke C, Stamer K, et al. (2015) Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration. Cell Mol Life Sci 72(11):2199-222.

Download

Melis V, Magbagbeolu M, Rickard JE, et al. (2015) Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol 26(4):353-68.

Download

Baddeley TC, McCaffrey J, Storey JMD, et al. (2015) Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer’s disease. J Pharmacol Exp Ther 352:1-9.

Download

Wischik CM, Staff RT, Wischik DJ, et al. (2015) Tau aggregation inhibitor therapy: an exploratory Phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimers Dis 44:705-720.

Download

Wischik CM, Harrington CR, Storey J. (2014) Tau-aggregation inhibitor for Alzheimer's disease. Biochem Pharmacol 88:529-539.

Download